Both in Pharmaceuticals
Arrowhead Research vs Cytokinetics
Over the past year ARWR returned +96.1% and CYTK returned +21.8%; their daily moves had a correlation of 0.30.
ARWR +96.1% CYTK +21.8%Growth of $1, one year, split-adjusted
| Metric | ARWR | CYTK |
|---|---|---|
| Price | $66.25 | $65.64 |
| Market cap | $9.36B | $9.13B |
| Today | +1.21% | −0.79% |
| 1 month | −22.0% | −8.9% |
| 6 months | +14.9% | +4.2% |
| Year to date | −0.2% | +3.3% |
| 1 year | +102.0% | +30.2% |
| Revenue growth (YoY) | +171.0% | −57.1% |
| Gross margin | 100.0% | 90.5% |
| Net margin | −258.2% | −694.4% |
| P/E (TTM) | — | — |
| Price / sales | 14.0× | 134.9× |
| Net cash | $737.9M | $18.6M |
| Dividend yield | — | — |
| Volatility (60d) | 62.0% | 33.7% |
| Short % of float | 6.8% | 14.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).